| Q54181615 | Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin. |
| Q40533711 | Altered DNA topoisomerase II in multidrug resistance |
| Q41301455 | An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein |
| Q40388183 | Anthracycline antibiotics in cancer therapy. Focus on drug resistance |
| Q41354275 | Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. |
| Q40708934 | Cellular models for multiple drug resistance in cancer |
| Q28369412 | Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening |
| Q92411750 | Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin |
| Q34207338 | Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours |
| Q36292935 | Determinants of CPT-11 and SN-38 activities in human lung cancer cells |
| Q55094275 | Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer. |
| Q35977182 | Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines? |
| Q36553263 | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer |
| Q54056994 | Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa. |
| Q36081137 | Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer |
| Q41522535 | Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes |
| Q48156853 | GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance. |
| Q35994568 | High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines |
| Q40535290 | Human cell lines as models for multidrug resistance in solid tumours |
| Q48505514 | Immunohistochemical markers for prognosis of oligodendroglial neoplasms |
| Q35782052 | Immunohistochemical study of DNA topoisomerase II in human gastric disorders |
| Q36140933 | In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model |
| Q36116478 | In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin |
| Q34914312 | In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. |
| Q33606082 | Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity |
| Q24629023 | Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24 |
| Q36080575 | Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells |
| Q41292266 | Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line |
| Q40696510 | Multilevel therapeutic targeting by topoisomerase inhibitors |
| Q24614785 | Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells |
| Q36740653 | Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients |
| Q41501298 | Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line |
| Q42590977 | Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines |
| Q54240069 | Resistance to cisplatin in an E. coli B/r NalR mutant |
| Q60049780 | Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining |
| Q36186309 | The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients |
| Q33743596 | Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer |
| Q40535267 | Topoisomerase II in multiple drug resistance |
| Q35770181 | Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma |
| Q40694357 | Topoisomerase expression in cancer cell lines and clinical samples |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
| Q35132390 | Two novel determinants of etoposide resistance in small cell lung cancer. |